REV3L confers chemoresistance to cisplatin in human gliomas: the potential of its RNAi for synergistic therapy
about
Suppression of Rev3, the catalytic subunit of Pol{zeta}, sensitizes drug-resistant lung tumors to chemotherapyExploiting the Fanconi Anemia Pathway for Targeted Anti-Cancer TherapySystems biology of cisplatin resistance: past, present and futureEukaryotic DNA polymerase ζDNA polymerases in the mitochondria: A critical review of the evidence.Analysis of specialized DNA polymerases expression in human gliomas: association with prognostic significance.REV3L 3'UTR 460 T>C polymorphism in microRNA target sites contributes to lung cancer susceptibility.Expression and prognostic significance of TCTN1 in human glioblastomaMicroRNA-377 inhibited proliferation and invasion of human glioblastoma cells by directly targeting specificity protein 1.Error-prone translesion synthesis mediates acquired chemoresistanceRAD52 variants predict platinum resistance and prognosis of cervical cancer.Resistance to therapy in BRCA2 mutant cells due to loss of the nucleosome remodeling factor CHD4.REV3L, a promising target in regulating the chemosensitivity of cervical cancer cells.Crosstalk between translesion synthesis, Fanconi anemia network, and homologous recombination repair pathways in interstrand DNA crosslink repair and development of chemoresistanceVAMP8 facilitates cellular proliferation and temozolomide resistance in human glioma cells.Human REV3 DNA Polymerase Zeta Localizes to Mitochondria and Protects the Mitochondrial Genome.A Comprehensive Review on the Genetic Regulation of Cisplatin-induced NephrotoxicityEnhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug.REV1 and DNA polymerase zeta in DNA interstrand crosslink repair.Cytoplasmic RAP1 mediates cisplatin resistance of non-small cell lung cancer.Co-inhibition of pol θ and HR genes efficiently synergize with cisplatin to suppress cisplatin-resistant lung cancer cells survival.Inhibition of REV3 expression induces persistent DNA damage and growth arrest in cancer cells.c-Myc-miR-29c-REV3L signalling pathway drives the acquisition of temozolomide resistance in glioblastoma.RNA interferences targeting the Fanconi anemia/BRCA pathway upstream genes reverse cisplatin resistance in drug-resistant lung cancer cells.DNA polymerase ζ as a potential biomarker of chemoradiation resistance and poor prognosis for cervical cancer.MicroRNA-340 inhibits the proliferation and promotes the apoptosis of colon cancer cells by modulating REV3L.Association of polymorphisms in translesion synthesis genes with prognosis of advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy.pH-Responsive Cross-Linked Low Molecular Weight Polyethylenimine as an Efficient Gene Vector for Delivery of Plasmid DNA Encoding Anti-VEGF-shRNA for Tumor TreatmentDNA repair pathways and cisplatin resistance: an intimate relationship
P2860
Q24631616-6D050352-4E39-4CBB-87D8-1995BFD7260DQ26801593-54913687-79CE-44FD-AB75-D164E53C0599Q26863585-A45A7BF5-D684-4C73-BACD-24E2E0679D86Q27011365-A656293A-B4CA-46D8-9AE8-06BBFC00C3E3Q33838032-ACCAF289-5933-4A98-AB4C-ACB99E891F30Q34132978-E331AC4F-E1A8-451A-B294-8E16E5A464B3Q34255750-BA7AE7A2-6AE8-4E8F-A00C-EC92FDCCC1CDQ34346091-5DA06CB3-8631-4F6D-A424-FF04C855A5F0Q34359701-5A2B5D8B-6AE4-4731-A697-EB0262718F28Q34376054-92B49587-3CD8-4499-B52C-66B4099FDC22Q34500320-18D68FF0-1CFB-4273-A66E-5F6BCDC69145Q35173275-9AF258DE-5297-48A5-92E6-2EF9F5700BC5Q35190445-8D5996CC-ADD4-482D-A8D3-5AAB6F50530AQ35205030-CD6075B4-4588-4B40-9199-EFC8198BDD1BQ35788911-6EC04D1C-E082-4129-B016-BF84639BF569Q35804949-17941C4D-83D1-469F-A59E-80C8D86AF626Q36906569-8DBC479E-B630-43A7-98CB-2B19CA83B533Q37319709-4BD9CFEE-0C48-49DF-B245-1D62F5EF358CQ38052100-D4DBE4E7-CB28-470A-A9AD-3DDE51BAC47DQ38703087-DDDF72A3-AB35-481C-97EB-A993AFA58593Q38751436-40D46E5D-19DB-4DC4-82E8-FBE7EE3B0D57Q38826337-9866C709-9BE5-40A9-81AB-49296283CBEAQ38829331-157D3645-D473-4649-B257-59EE0236FB9CQ38834205-7309EA67-6C73-42A0-A7D9-EA2282B8A59FQ45832606-FD766A3B-5B83-4358-B79E-0DD5C5CBA846Q49779139-76EA9954-895D-4EDE-A5E0-577323B93705Q51570234-6A712BBD-55A0-4D00-9C1A-A4FA7742F883Q57492127-F3808820-87AB-4A43-9B96-8D920910193BQ58699219-44AF77DE-9256-4337-AD34-0E067A0D22B5
P2860
REV3L confers chemoresistance to cisplatin in human gliomas: the potential of its RNAi for synergistic therapy
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
REV3L confers chemoresistance ...... s RNAi for synergistic therapy
@ast
REV3L confers chemoresistance ...... s RNAi for synergistic therapy
@en
REV3L confers chemoresistance ...... RNAi for synergistic therapy.
@nl
type
label
REV3L confers chemoresistance ...... s RNAi for synergistic therapy
@ast
REV3L confers chemoresistance ...... s RNAi for synergistic therapy
@en
REV3L confers chemoresistance ...... RNAi for synergistic therapy.
@nl
prefLabel
REV3L confers chemoresistance ...... s RNAi for synergistic therapy
@ast
REV3L confers chemoresistance ...... s RNAi for synergistic therapy
@en
REV3L confers chemoresistance ...... RNAi for synergistic therapy.
@nl
P2093
P2860
P1433
P1476
REV3L confers chemoresistance ...... s RNAi for synergistic therapy
@en
P2093
Huibo Wang
Jingmin Yang
Shiguang Zhao
Shu-Yu Zhang
Shuai Wang
P2860
P304
P356
10.1215/15228517-2009-015
P50
P577
2009-12-01T00:00:00Z